Tonix Pharmaceuticals Holding Corp.
TNXP · NASDAQ
Market closed$12.43$0.580000 (+4.89%)After hours $12.42 · -0.08%
Key statistics
Previous close$11.85
Open$11.65
Day high$12.76
Day low$11.64
52-week high$69.97
52-week low$10.03
Market cap198.14M
Volume682.06K
Average volume499.12K
P/E ratio-0.87
Forward P/E—
EPS-14.36
Dividend yield0.00%
Market context
Why it moved
TNXP rose on continued positive momentum driven by strong technical buy signals and growing investor interest in Tonix Pharmaceuticals as a penny stock play, supported by rising volume confirming the upward trend.
What is happening
Recent company-specific developments and publisher coverage.
Stock Titan · July 15, 2026Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine ResearchGlobeNewswire · July 15, 2026Tonix Pharmaceuticals Announces Publication in theQuiver Quantitative · July 13, 2026Tonix Pharmaceuticals Announces Major Medicare Coverage Agreement for TONMYA, Expanding U.S. Access to Approximately 145 Million Covered LivesInvesting.com · June 24, 2026Raymond James initiates Tonix Pharma stock coverage with strong buyStock Titan · June 11, 2026Fibromyalgia drug developer Tonix plans 1x1 talks at infectious disease eventStock Titan · June 8, 2026First new fibromyalgia medicine in over 15 years now covered for 52M peopleStock Titan · May 12, 2026Fibromyalgia and Lyme biotech Tonix lines up two May investor talksStocktwits · May 6, 2026Why TNXP Stock Is Suddenly Back On Retail Radar Benzinga · July 15, 2026Tonix Pharma Announces Publication Of Monkeypox Study In Journal Of Virology, Peer-Reviewed Publication Of ASM Mt Newswire · July 13, 2026Tonix Pharmaceuticals Reaches Medicare Coverage Deal for Fibromyalgia Treatment Benzinga · July 13, 2026Tonix Secures Medicare Coverage For Fibromyalgia Drug TONMYA, Expands TONMYA Coverage To 145M Lives By 2027 Mt Newswire · June 29, 2026Tonix Pharmaceuticals Advances TNX-102 SL Into Phase 2 MDD Study Mt Newswire · June 25, 2026Raymond James Initiates Coverage on Tonix Pharmaceuticals With Strong Buy Rating, $26 PT Benzinga · June 25, 2026Raymond James Initiates Coverage On Tonix Pharmaceuticals with Strong Buy Rating, Announces Price Target of $26 Benzinga · June 8, 2026Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA Mt Newswire · June 8, 2026Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage